1457 related articles for article (PubMed ID: 26966191)
21. MYC: Master Regulator of Immune Privilege.
Casey SC; Baylot V; Felsher DW
Trends Immunol; 2017 Apr; 38(4):298-305. PubMed ID: 28233639
[TBL] [Abstract][Full Text] [Related]
22. Reversing Immune Suppression and Potentiating Photothermal Immunotherapy via Bispecific Immune Checkpoint Inhibitor Loaded Hollow Polydopamine Nanospheres.
Guo K; Chen D; Ren S; Younis MR; Teng Z; Zhang L; Wang Z; Tian Y
ACS Appl Mater Interfaces; 2023 Mar; ():. PubMed ID: 36881613
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy induces enrichment of CD47
Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
[TBL] [Abstract][Full Text] [Related]
24. Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation.
Wang JY; Jiang MW; Li MY; Zhang ZH; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Jin HL; Ma J; Jin Y; Zuo HX; Jin X
J Nutr Biochem; 2022 Feb; 100():108899. PubMed ID: 34748924
[TBL] [Abstract][Full Text] [Related]
25. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
Li Y; Wang J; Li C; Ke XY
Leuk Lymphoma; 2012 Oct; 53(10):2015-23. PubMed ID: 22462616
[TBL] [Abstract][Full Text] [Related]
26. Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Xu Y; Poggio M; Jin HY; Shi Z; Forester CM; Wang Y; Stumpf CR; Xue L; Devericks E; So L; Nguyen HG; Griselin A; Gordan JD; Umetsu SE; Reich SH; Worland ST; Asthana S; Barna M; Webster KR; Cunningham JT; Ruggero D
Nat Med; 2019 Feb; 25(2):301-311. PubMed ID: 30643286
[TBL] [Abstract][Full Text] [Related]
27. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Xiong W; Deng H; Huang C; Zen C; Jian C; Ye K; Zhong Z; Zhao X; Zhu L
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):454-463. PubMed ID: 30385408
[TBL] [Abstract][Full Text] [Related]
28. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Sumimoto H; Takano A; Teramoto K; Daigo Y
PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
[TBL] [Abstract][Full Text] [Related]
29. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
Wang Y; Ni H; Zhou S; He K; Gao Y; Wu W; Wu M; Wu Z; Qiu X; Zhou Y; Chen B; Pan D; Huang C; Li M; Bian Y; Yang M; Miao L; Liu J
Cancer Immunol Immunother; 2021 Feb; 70(2):365-376. PubMed ID: 32761423
[TBL] [Abstract][Full Text] [Related]
30. Concurrent Expression of CD47 and CD44 in Colorectal Cancer Promotes Malignancy.
Fujiwara-Tani R; Sasaki T; Ohmori H; Luo Y; Goto K; Nishiguchi Y; Mori S; Nakashima C; Mori T; Miyagawa Y; Kawahara I; Fujii K; Kishi S; Tatsumoto N; Kuniyasu H
Pathobiology; 2019; 86(4):182-189. PubMed ID: 31132784
[TBL] [Abstract][Full Text] [Related]
31. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer.
Liu B; Cao W; Qiao G; Yao S; Pan S; Wang L; Yue C; Ma L; Liu Y; Cui D
Acta Biomater; 2019 Nov; 99():307-319. PubMed ID: 31513911
[TBL] [Abstract][Full Text] [Related]
32. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
[TBL] [Abstract][Full Text] [Related]
33. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.
Hsieh RC; Krishnan S; Wu RC; Boda AR; Liu A; Winkler M; Hsu WH; Lin SH; Hung MC; Chan LC; Bhanu KR; Srinivasamani A; De Azevedo RA; Chou YC; DePinho RA; Gubin M; Vilar E; Chen CH; Slay R; Jayaprakash P; Hegde SM; Hartley G; Lea ST; Prasad R; Morrow B; Couillault CA; Steiner M; Wang CC; Venkatesulu BP; Taniguchi C; Kim YSB; Chen J; Rudqvist NP; Curran MA
Sci Immunol; 2022 Jun; 7(72):eabl9330. PubMed ID: 35687697
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.
Huang TH; Mokgautsi N; Huang YJ; Wu ATH; Huang HS
Cells; 2021 Aug; 10(8):. PubMed ID: 34440739
[TBL] [Abstract][Full Text] [Related]
35. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
36. Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
Sasi B; Ethiraj P; Myers J; Lin AP; Jiang S; Qiu Z; Holder KN; Aguiar RCT
Leukemia; 2021 Jul; 35(7):1990-2001. PubMed ID: 33299141
[TBL] [Abstract][Full Text] [Related]
37. MYC Promotes Tumorigenesis via Activation of CD47 and PD-L1.
Cancer Discov; 2016 May; 6(5):472. PubMed ID: 27012831
[TBL] [Abstract][Full Text] [Related]
38. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
Lian S; Xie R; Ye Y; Lu Y; Cheng Y; Xie X; Li S; Jia L
Sci Rep; 2019 Mar; 9(1):4532. PubMed ID: 30872703
[TBL] [Abstract][Full Text] [Related]
39. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.
Zhang Y; Xie X; Yeganeh PN; Lee DJ; Valle-Garcia D; Meza-Sosa KF; Junqueira C; Su J; Luo HR; Hide W; Lieberman J
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
